Similar articles

• To treat osteoporosis, Denosumab appears more effective than Zoledronate. Denosumab has the advantage in building bone density, and has fewer side effects.

  [No authors listed] [No authors listed] Duke Med Health News. 2014 Mar;20(3):1-2. Duke Med Health News. 2014. PMID: 24683617 No abstract available.
• Biennial [corrected] IV zoledronic acid (Reclast) for prevention of osteoporosis.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2009 Jun 29;51(1315):49. Med Lett Drugs Ther. 2009. PMID: 19556940 No abstract available.
• Zoledronic acid--once-yearly. Corticosteroid-induced osteoporosis: no benefit.

  [No authors listed] [No authors listed] Prescrire Int. 2010 Apr;19(106):63. Prescrire Int. 2010. PMID: 20568485 No abstract available.
• [New bone density conservation agents for osteoporosis under research and development: ED-71].

  Hagino H. Hagino H. Nihon Rinsho. 2007 Nov 28;65 Suppl 9:454-8. Nihon Rinsho. 2007. PMID: 18161148 Review. Japanese. No abstract available.
• [New bone density conservation agents for osteoporosis under research and development: Strontium ranelate].

  Shiraki M. Shiraki M. Nihon Rinsho. 2007 Nov 28;65 Suppl 9:447-53. Nihon Rinsho. 2007. PMID: 18161147 Review. Japanese. No abstract available.